Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
First Tracks BiotherapeuticsMEX:TRAX 12 Cash Ratio is 10.65 as of Dec. 2024, which is 34% below its 10-year median of 16.05. GuruFocus rates MEX:TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,328 Biotechnology companies, First Tracks Biotherapeutics ranks better than 81.55% on this metric.
First Tracks Biotherapeutics has a Cash Ratio of 10.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for First Tracks Biotherapeutics's Cash Ratio or its related term are showing as below:
MEX:TRAX'
s Cash Ratio Range Over the Past 10 Years
Min: 10.65 Med: 16.05 Max: 21.45
Current: 10.65
During the past 2 years, First Tracks Biotherapeutics's highest Cash Ratio was 21.45. The lowest was 10.65. And the median was 16.05.
MEX:TRAX's Cash Ratio is ranked better than 81.55% of 1328
companies
in the Biotechnology industry
Industry Median: 3.03
vs MEX:TRAX: 10.65
First Tracks Biotherapeutics (MEX:TRAX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
First Tracks Biotherapeutics Cash Ratio Related Terms
First Tracks Biotherapeutics Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Cash Ratio Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Cash Ratio
21.45
10.65
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Cash Ratio
21.45
10.65
MEX:TRAX vs AVLN, IMTX, ARDX: Cash Ratio Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics (MEX:TRAX) has a Cash Ratio of 10.65 as of Dec. 2024. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on First Tracks Biotherapeutics and its competitors. This is 34% below median its historical median of 16.05. Over the past decade, First Tracks Biotherapeutics' Cash Ratio has ranged from 10.65 to 21.45. According to the industry distribution chart, First Tracks Biotherapeutics ranks #245 out of 1328 companies in the Biotechnology industry, placing it in the top 18.4%.
Is First Tracks Biotherapeutics' Cash Ratio too high?
First Tracks Biotherapeutics' current Cash Ratio of 10.65 is 34% below median its 10-year median of 16.05. Over the past 10 years, this metric has ranged from a low of 10.65 to a high of 21.45. The Biotechnology industry median Cash Ratio is 3.03. First Tracks Biotherapeutics' value of 10.65 is 251.5% above this industry median. Based on the distribution chart, First Tracks Biotherapeutics ranks #245 out of 1328 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Cash Ratio compare to AVLN and IMTX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #245 out of 1328 companies for Cash Ratio. This places First Tracks Biotherapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 3.03. First Tracks Biotherapeutics' value of 10.65 is 251.5% above this benchmark. Historically, First Tracks Biotherapeutics' own Cash Ratio has ranged from 10.65 to 21.45 over the past decade. While the company's 10-year median is 16.05 vs. the industry median of 3.03, First Tracks Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.03, based on 1,328 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. First Tracks Biotherapeutics's current Cash Ratio of 10.65 is 251.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Cash Ratio is 10.65, which is 34% below median its own 10-year median of 16.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (MEX:TRAX) has a current Cash Ratio of 10.65. The current Cash Ratio is 10.65, which is 34% below median its 10-year median of 16.05 and 251.5% above the Biotechnology industry median of 3.03. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For First Tracks Biotherapeutics (MEX:TRAX), the current Cash Ratio is 10.65 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score
Get the complete analysis for MEX:TRAX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TRAX has been successfully added to your 
